Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 11;17(4):508.
doi: 10.3390/pharmaceutics17040508.

Nanomedicine-Enhanced Radiotherapy for Glioblastoma: Advances in Targeted Therapy and Adaptive Treatment Strategies

Kamila Rawojć  1 , Mansoor M Ahmed  2 , Ayesha Mukhtiar  3 , Magdalena Łukowiak  4 , Kamil Kisielewicz  1
Affiliations
Review

Nanomedicine-Enhanced Radiotherapy for Glioblastoma: Advances in Targeted Therapy and Adaptive Treatment Strategies

Kamila Rawojć et al. Pharmaceutics. .

Abstract

Glioblastoma multiforme remains one of the most aggressive and treatment-resistant brain tumors that necessitate innovative therapeutic approaches. Nanomedicine has emerged as a promising strategy to enhance radiation therapy by improving drug delivery, radiosensitization, and real-time treatment monitoring. Stimuli-responsive nanoparticles can overcome limitations of the blood-brain barrier, modulate tumor microenvironment, and facilitate targeted therapeutic interventions. The integration of nanotechnology with proton and X-ray radiotherapy offers improved dose precision, enhanced radiosensitization, and adaptive treatment strategies. Furthermore, Artificial Intelligence-driven nanoparticle designs are optimizing therapeutic outcomes by tailoring formulations to tumor-specific characteristics. While promising, clinical translation remains a challenge that requires rigorous validation to ensure safety and efficacy. This review highlights advancements in nanomedicine-enhanced radiotherapy and future directions for glioblastoma multiforme treatment.

Keywords: adaptive radiotherapy; blood–brain barrier (BBB); glioblastoma multiforme (GBM); golden nanopeanuts; hypoxia-targeting nanomedicine; immunogenic cell death (ICD); immunotherapy; nanomedicine; personalized oncology; proton therapy; radiosensitization; redox-responsive nanocarriers; stimuli-responsive nanoparticles; tumor microenvironment (TME).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Nanomedicine-enhanced strategies for glioblastoma therapy. Schematic representation of core applications of nanomedicine in the treatment of glioblastoma.
Figure 2
Figure 2
Advances in research in nanomedicine-enhanced radiotherapy for glioblastoma, including mechanisms of radiosensitization, tumor microenvironment targeting, and integration with adaptive radiotherapy modalities.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ostrom Q.T., Cioffi G., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. Neuro-Oncology. 2021;23:iii1–iii105. doi: 10.1093/neuonc/noab200. - DOI - PMC - PubMed
    1. Brown J.M., Wilson W.R. Exploiting Tumour Hypoxia in Cancer Treatment. Nat. Rev. Cancer. 2004;4:437–447. doi: 10.1038/nrc1367. - DOI - PubMed
    1. Dolores H., Bergers G. Glioblastoma: Defining Tumor Niches. Trends Cancer. 2015;1:252–265. doi: 10.1016/j.trecan.2015.10.009. - DOI - PMC - PubMed
    1. Roger S., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J.B., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 2005;352:987–996. doi: 10.1056/nejmoa043330. - DOI - PubMed
    1. Liu B., Liu J. Surface Modification of Nanozymes. Nano Res. 2017;10:1125–1148. doi: 10.1007/s12274-017-1426-5. - DOI

LinkOut - more resources